DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

NIR-Guided Sentinel Lymph Node Mapping in Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: ICG Intervention

First Posted Date: 2010-05-12

Last Posted Date: 2017-02-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 26

Registration Number: NCT01121718

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: Lexiscan

First Posted Date: 2010-03-11

Last Posted Date: 2014-03-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 39

Registration Number: NCT01085201

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Childrens Hospital Boston, Boston, Massachusetts, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 4 locations

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Leukemia

Interventions: Drug: pyrimethamine

First Posted Date: 2010-02-10

Last Posted Date: 2023-02-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT01066663

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Panobinostat (LBH589) in Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma
Malignant Melanoma

Interventions: Drug: LBH589

First Posted Date: 2010-02-09

Last Posted Date: 2017-03-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 16

Registration Number: NCT01065467

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Gastrointestinal Cancer

Interventions: Drug: Everolimus
Drug: Tivozanib

First Posted Date: 2010-01-29

Last Posted Date: 2017-04-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 56

Registration Number: NCT01058655

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer

Phase 1

Terminated

Conditions: Head and Neck Cancer

Interventions: Radiation: Intensity modulated radiotherapy
Drug: RAD001
Drug: cisplatin

First Posted Date: 2010-01-28

Last Posted Date: 2013-02-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT01058408

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Phase 2

Completed

Conditions: Pancreatic Neuroendocrine Tumor
Neuroendocrine Tumor
Carcinoid Tumor

Interventions: Drug: AMG 479

First Posted Date: 2009-12-02

Last Posted Date: 2018-03-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT01024387

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases

Phase 2

Completed

Conditions: Progressive Breast Cancer
Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: carboplatin
Drug: bevacizumab
Drug: herceptin

First Posted Date: 2009-10-29

Last Posted Date: 2018-12-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 38

Registration Number: NCT01004172

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

Phase 2

Terminated

Conditions: Sickle Cell Disease
Sickle Cell Anemia

Interventions: Drug: vorinostat

First Posted Date: 2009-10-22

Last Posted Date: 2017-07-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT01000155

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: RAD001

First Posted Date: 2009-09-14

Last Posted Date: 2018-10-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 33

Registration Number: NCT00976248

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy